Skip to content

Acupucture of "Si-Guan points" combined with Fentanyl Transdermal System (duragesic) for the moderate to severe cancer pain: a randomized controled phase III study

Acupucture of "Si-Guan points" combined with Fentanyl Transdermal System (duragesic) for the moderate to severe cancer pain: a randomized controled phase III study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005494
Enrollment
Unknown
Registered
2014-11-10
Start date
2014-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

"Si-Guan Points" combined with Fentanyl Transder:Acupucture "Si-Guan Points" combined with Fentanyl Transdermal System (duragesic)
Fentanyl Transdermal System (duragesic) Group:Fentanyl Transdermal System (duragesic)

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. without chemotherapy or radiotherapy in 3 weeks; 2. age 18 years or older, gender is not limited; 3. without mental diseases and can evaluate pain; 4. estimated lifetime for 3 months or more; 5. signed informed consent.

Exclusion criteria

Exclusion criteria: 1. the paint is no related to the cancer or the treatment; 2. have difficulty judging pain, mental retardation or mental illness; 3. Children, pregent women or children, pregnant and lactating women; 4. having other severe primary disease; 5. patients with bone metastasis receiving internal radiation therapy and/or receiving bisphosphonates drug therapy receiving within 4 weeks; 6. respiratory depression, (lung) airway obstruction or tissue hypoxia; 7. bile duct diseases; 8. heart disease (heart function level II and level II or above); 9. the blood pressure is higher than normal level; 10. hematological diseases; 11. the liver and renal function abnormal (the index is higher than normal 1 time times); 12. with mental disease who can not judge the pain; 13. fentanyl drug allergy; 14. the drug fentanyl drug tolerance; 15. drug and/or alcohol abuse; 16. pregnant or lactating women; 17. refuse treated with acupuncture and moxibustion.

Design outcomes

Primary

MeasureTime frame
Numeric rating scale;

Secondary

MeasureTime frame
The Quality of Lif;adverse reaction;The total amount of opiates;

Countries

China

Contacts

Public ContactLizhu Lin
lizhulin903@21cn.com+86 020 36596360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026